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Abstract: 
 Many different factors contribute to the development and progression of 
heart disease. Although substantial advancements have recently been established 
in the treatment and prevention of heart disease, it continues to produce one in 
every four deaths in the United States3. This indicates a growing need for 
treatment options for both cardiovascular disease and its related complications. 
Human Amniotic Material (HAM) presents a treatment option for the preservation 
of myocardial functionality as well as prevention of post-operative pericardial 
inflammation and development of altered electrical activity in the heart. Our 
research has shown that the application of HAM led to a significant reduction in 
the development of post-operative atrial fibrillation in humans undergoing cardiac 
surgery. Furthermore, HAM injection in an ischemic mouse model led to reduced 
pathological remodeling of the left ventricle, demonstrating its ability to improve 
the retention of cardiac function in ischemic tissues.  
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Chapter 1: Introduction  
General Background: 
 Cardiovascular disease is currently the leading cause of death in the 
United States, outnumbering both cancer and unintentional injuries, the second 
and third leading causes combined. It is estimated that 45.1% of the United 
States’ population will have cardiovascular disease by the year 2035, with the 
subsequent healthcare cost increasing from approximately $351 billion to $1.1 
trillion4. Although incidence rates have declined in the last few decades due to 
advances in treatment and prevention5, it is apparent that cardiovascular disease 
will persist throughout the United States population, and a need for the 
development of novel treatments will continue to be a top-priority research area.  
Myocardial infarction (MI) is produced by the occlusion of a blood vessel 
limiting the oxygen exchange in the myocardium, creating an area of ischemia 
where the tissue does not receive the blood flow necessary to survive and/or 
function normally. This leads to the loss of cardiomyocytes and inability of the 
ventricular wall to contract and function at the degree required to pump a 
sufficient amount of blood to the rest of the body; thereby contributing to the 
progression of heart failure. Early revascularization is proven to be crucial to 
effectively salvaging myocardium from necrosis and reducing infarct size. 
However, when blood flow is restored to the area of infarct, further damage and 
necrosis occurs, categorized as ischemia reperfusion (IR) injury. Although 
revascularization is vital in limiting the infarct size and preventing long term heart 
failure, the process also leads to further loss of cardiomyocytes as illustrated in 
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Figure 1. The mechanism of IR injury is a rise in oxygen-derived free radicals 
and calcium overloading, which then further damage the already at-risk tissue 
resulting in the IR injury1. 
Reperfusion injury is also in part 
due to the inflammation triggered 
by the return of blood flow to the 
damaged myocytes, resulting in 
accumulation of neutrophils in 
numbers directly correlated to the 
duration of the ischemic event6. 
Inflammation plays a crucial role in the progression of the infarct and the 
remodeling that occurs in the affected tissue. The infiltration of neutrophils then 
leads to a further increase in reactive oxygen species, as well as release of 
inflammatory mediators and the no-reflow phenomenon, in which distal blood 
vessels experience additional blockages7. Inflammation may also instigate the 
alteration of electrical activity of the heart, triggering new onset post-operative 
atrial fibrillation (POAF). Although the cause of POAF is relatively unknown, 
studies suggest that inflammation is a strong contributing factor8. During cardiac 
surgery it is necessary to rupture the pericardial sac that surrounds and protects 
the heart from friction and foreign debris. Disruption of this barrier leads to the 
infiltration of cells and debris into the fluid within the pericardial sac. This results 
in local inflammation surrounding the heart, which then promotes cardiomyocyte 
death and the alteration of electrical activity that then generates arrhythmias9. 
Figure 1: (Maxwell SRJ) A representation of the 
progression of myocyte death during ischemia and after 
reperfusion.  
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Animal models have displayed a direct correlation between the extent of 
inflammation and the prevalence of POAF. 
POAF is known to occur in approximately 35% of cardiac surgery 
patients9, although recent studies have estimated that the occurrence rate is up to 
50% due to underestimation and lack of diagnosis10,11. POAF is correlated with 
several undesirable outcomes, such as a two-fold increase in the risk of 
cardiovascular mortality, a 2.3-fold increase in the risk of stroke, and a five-fold 
increase in risk for congestive heart failure12. It poses a higher risk for renal 
failure and sudden cardiac death12, along with significantly longer hospital stays, 
hospital costs, and hospital readmission rates13. Efforts to reduce the incidence 
rates of POAF after cardiac surgery have proven to be ineffective, with rates 
seeing little to zero decline. Given its strong correlation with poor patient 
outcomes and higher overall costs, additional research into the prevention and 
management of POAF is essential to improving patient outcomes. 
Current treatment of POAF include the use of beta-blockers, calcium 
channel blockers, positive inotropes (i.e. digoxin), and anti-arrhythmic (i.e. 
amiodarone). Electrical cardioversion is also used in patients that are not 
hemodynamically stable but presents undesirable risks to the patients such as 
stroke and additional medication, so it is usually a last-resort method. Beta-
blockers and calcium channel blockers are normally the first-line-drugs used to 
treat POAF, however it is not uncommon for the drugs to be ineffective or poorly 
tolerated in patients with systolic heart failure14. Anti-arrhythmic drugs such as 
amiodarone can cause bradycardia and hypotension and is therefore not suitable 
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for use in all patients15. Digoxin is used to slow the heart rate and control the heart 
rhythm but is not very effective in instances with higher sympathetic tone such as 
after invasive surgery16. Anticoagulation therapy is also a treatment option if 
POAF persists longer than 48 hours, but it is necessary to take into consideration 
the risk of bleeding after a major cardiac surgery. Corticosteroids are used to 
combat inflammation if it is detected and severe enough to warrant treatment, but 
their use is limited as they are associated with infection and hyperglycemia17. 
Cardiac ablation is only used in severe and chronic cases of atrial fibrillation and 
therefore is not used for POAF treatment. All current and commonly used 
treatment therapies for POAF come with severe risks and undesirable side effects. 
HAM application during cardiac surgery could offer a solution for prevention of 
post-operative inflammation and atrial fibrillation with minimal risks associated 
with its uses.  
 
Human Amniotic Material: 
Human Amniotic Material (HAM) presents a possible solution for the 
need of novel treatments post cardiac surgery, particularly following myocardial 
infarct intervention surgery. HAM has a very low immunogenicity while offering 
anti-inflammatory, antibacterial, anti-adhesion and anti-fibrotic capabilities that 
may limit pathological remodeling pathways18. HAM has a long history of use for 
wound dressings as it offers an allograft filled with growth factors and 
components to help speed healing while also providing a barrier that is 
biocompatible and combats infection.  
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The innermost layer of the placenta contains the amnion which is in direct 
contact with the amniotic fluid and fetus during gestation. The chorion is located 
at a more superficial level, loosely connected to the amnion19. The amnion layer 
comprises live amnion cells, cytokines, proteins, growth factors, extracellular 
matrix, fibronectin, elastin, laminin, nidogen and multipotent cells. These 
components are essential for cell scaffolds, as well as the promotion of regrowth 
and healing. The amnion contains epithelial and mesenchymal amniotic cells that 
secrete anti-inflammatory proteins such as Activin A, and IL-10, along with a 
notable suppression of proinflammatory cytokines, and expression of IL-1α and 
IL-1β, all contributing to its anti-inflammatory properties20. Amniotic tissue also 
produces β-defensins, a major group of antimicrobial peptides leading to the anti-
microbial properties of the material21. Amniotic material limits the activation of 
fibroblasts through the suppression of TGF-β and the receptor expression on 
fibroblasts, which activate fibroblasts and lead to fibrosis, resulting in the 
material’s anti-scarring property22. Although cells in the amnion have been shown 
to produce an extremely mild immune response, this response is counteracted by 
the presence of immunoregulatory factors listed above. Because the amnion and 
chorion layers separate the fetus from the immune system of the mother, it is 
necessary for the material to have low immunogenicity in order to prevent mother 
and fetus from producing an immune response23. Amniotic epithelial cells, for 
example, express HLA-G antigens which do not elicit an immune response 
instead of HLA-A, HLA-B, or HLA-DR antigens that are immunogenic and 
would be typical expressions of the cell type24,25.  
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The chorion layer consists mostly of a dense collagen matrix; it contains a 
collection of growth factors and cytokines very similar to that of the amnion layer, 
but because the chorion is much thicker, it provides a larger amount of those 
desired components26. The addition of the chorion layer thereby offers 
significantly more growth factors and cytokines effective in boosting healing 
processes, while the amnion provides more of a vast array of contributing features 
to the suppression of inflammation and scarring22,27. However, the chorion has 
been known to cause an antigen response, and although it is mild, many 
processing methods isolate the amnion so that immune reactions are kept to a 
minimum. When the material is dehydrated it reduces the antigen response, due to 
the processing methods stripping and decellularizing the material, which is why 
many of the dehydrated versions include the chorion layer.  
HAM tissue grafts contain the amnion layer, or a combination of the 
amnion and chorion layers of the placenta. HAM is commercially available and 
produced from donated placental material in three general formats implemented in 
our studies. Two of these classify as a membrane allograft that is adhered to the 
tissue surface upon treatment; the dehydrated version which includes derivatives 
from the amnion and chorion layers of the placenta, and the viable version which 
includes amnion material only, with the addition of a live stem cell layer adhered 
to the scaffold of extracellular matrix. The third format is an injectable solution 
that is a liquid allograft suspension of the material derived from the amnion, the 
injection serves the purpose of increasing infiltration of the material into the tissue 
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and therefore enhancing the delivery of the anti-scarring and anti-inflammatory 
material deeper into the tissue.  
 
Previous Research: 
For over a century, amniotic material has been used to accelerate wound 
healing and serves as a contributing factor to the regenerative processes, leading 
to improved patient outcomes28. Interestingly, HAM is considered an allograft, 
but it has been documented to be equally effective as autologous skin grafts, with 
superior engraftment in comparison to other allografts29. Furthermore, the 
injection of amniotic cells and membrane matrix into chronic fibrotic scar tissue 
showed significant tissue remodeling and total elimination of pain relating to the 
scar tissue30. This indicates that injection of the amnion material may contribute 
to a reduction in scar tissue even in late-stage fibrosis. Applying these properties 
to cardiac repair has only recently become a topic of investigation and may offer a 
solution to lessen the damaging effects of remodeling after infarct.  
In a recent three-month-long study performed on ischemic rats, the 
animals treated with amniotic cells and membrane showed improved cardiac 
function, both systolic and diastolic, and reduced scar formation at the 30-day 
evaluation31. It was hypothesized that the amnion membrane serving as a scaffold 
would enhance cell engraftment and keep scar formation to a minimum on a more 
long-term timeline. However, the 90-day evaluation revealed that the scar 
formation and ejection fraction was no longer statistically significant from the 
non-treated group and no cell engraftment was observed31.  
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More recently, it has been observed that the application of amniotic 
membrane to the epicardial surface during cardiac surgery has reduced the 
amount of post-operative inflammation. This is shown in Figure 2 with arrows 
indicating the area of inflammation and reduced inflammation in the area 
surrounding the heart in the patient that received an amniotic membrane during 
cardiac surgery2. This case study was published as a proof-of-concept trial in 
which a 24-year-old patient suffering from pericarditis due to prior transplantation 
received pericardial stripping and adhesiolysis treatment with the addition of 
HAM placement. This patient showed reduced inflammation post-operatively and 
lack of development of POAF in comparison to a 56-year-old Coronary Artery 
Bypass Graft (CABG) recipient who went on to exhibit POAF. Although these 
patients are not closely comparable due to their differences, the data suggest that 
HAM placement could reduce inflammation after cardiac surgery. Due to the 
Figure 2: (Khalpey 2015) T2-weighted MRI obtained on post-operative day 6 of 56-year-old 
patient who did not receive amniotic membrane (A, B) and the 24-year-old patient who received 
an amniotic patch perioperatively (C, D). A, C with fat suppression B, D without fat 
suppression to localize edema. 
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large contribution of inflammation in the suggested mechanism of post-operative 
atrial fibrillation motivated further study of POAF occurrence rates in patients 
receiving amniotic membrane placement during cardiac surgery.  
Ninety-three eligible patients undergoing CABG or valve surgery (n=57 
and n=36 respectively) were included in a single-surgeon study to further explore 
the observed reduction in inflammation and absence of POAF manifestation due 
to amniotic allograft placement. As predicted by previous research, patients 
receiving valve surgery experienced a higher rate of POAF occurrence in the 
control group than that of the CABG group. The application of the amniotic 
allograft led to elimination of POAF occurrence in valve patients and a large 
reduction in the incidence rate of CABG patients, as shown in Figure 3 and 
Figure 4 below (unpublished data). This data shows the incidence rate of POAF 
can be significantly reduced by the application of HAM on the cardiac surface at 
the end of operation. However, it cannot be determined if inclusion of the chorion 
layer of the placenta reduces this incidence rate further, which would require 
further exploration. This is the first indication that POAF could possibly be 
treated by the application of HAM. The observed outcomes warranted additional 
research into the resulting mechanism due to the addition of amniotic membrane 
allografts. Research revealing the mechanism for improved outcomes would allow 
for the optimization of those processes in order to best fit the need of the patients. 
Although HAM application has recently been explored in cardiac diseased animal 
models, further analysis into the benefits and possible risks of its treatment is 
needed to be able to apply HAM in not only POAF treatments, but other cardiac 
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complications as well. The mechanisms provided by the introduction of HAM to 
the myocardial tissue are necessary to determine the full range of benefits 
provided by HAM. To explore this mechanism, however, it is necessary to turn to 
animal models to be able to perform in-depth studies of the material’s 
regenerative processes and integration into myocardial treatment areas. 
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Figure 3: Schematic of the occurrence rates of POAF and its correlated conditions 
including stroke and death in CABG procedures with 21 control patients, 30 patients that 
received amniotic membrane allografts, and 6 recipients of amnion/chorion allografts.  
Figure 4: Representation of POAF rates in valve patients including stroke and death 
rates. Valve patient numbers consisted of 15 control without treatment, 16 amniotic 
membrane allograft recipients, and 5 amnion/chorion membrane allograft recipients.  
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Specific Aims and Objectives: 
The goals of this research focused on exploring the mechanistic basis for 
the observation that placement of human amniotic membrane allografts on the 
epicardial surface during cardiac surgery led to a reduction in post-operative 
inflammation and POAF. This was examined through its use in two animal 
models with cardiac disease: permanently ligated ischemic mice, and ischemia 
reperfusion models in swine to represent coronary artery disease. These models 
were used to elucidate cellular and molecular mechanisms of HAM allografts as 
well as the contribution of HAM allografts to the preservation of cardiac function. 
These mechanisms were studied using echocardiography for functional 
assessment and histology for examination of material integration and its 
associated enhancement and suppression of specified cellular pathways. The 
overarching hypothesis of this research is that the use of HAM in ischemic 
cardiac tissue would reduce inflammation and scar formation, leading to a greater 
retention in cardiac function. In the next chapters I will discuss two animal 
models that were used to explore the more long-term remodeling pathways 
through a mouse model (Chapter 2) and the acute processes in a swine model 
(Chapter 3). Chapter 4 then includes a general discussion of the research we 
performed and the future directions of HAM research in cardiac applications.  
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Chapter 2: In vivo Mouse Model 
  
Materials and Methods   
All experiments followed guidelines for the use of laboratory animals and 
were approved by the Institutional Animal Care and Use Committee (IACUC) at 
the University of Arizona. The goals of this experiment included the examination 
of long-term implications of HAM use in both membrane and injection formats 
with ischemic mice models. Due to the reduction in POAF occurrence seen in the 
human applications, we hypothesized that the material will reduce immune 
responses initiated by the ischemia and surgery. Therefore, when applied to the 
infarction, the immune response is reduced, myocardial tissues are preserved, and 
scar formation will be reduced long-term. To test this, we used a permanent 
ligation mouse model over a timeline of one month to allow for remodeling to 
occur. To examine the scar formation, we used histological picrosirius red 
staining of collagen in contrast to cardiac tissue. For a closer look at the immune 
response, we used IL-6 (a tissue injury or infection related cytokine32) and CD68 
(a marker for macrophages) histology staining. Finally, for an indication of 
myocardial preservation, we used echocardiography for functional assessments 
and cardiac measurements. 
 
Experimental Design: 
An adult male mouse model was used to explore the contribution of the 
Human Amniotic Material to the preservation of cardiac function and the overall 
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remodeling of the myocardium at risk due to the occlusion of the Left Anterior 
Descending (LAD) artery. This model suggests a primarily long-term process of 
remodeling and the progression to heart failure seen in many cardiac disease 
patients.  
Three-month-old male mice (N=25) were anesthetized with an IP injection 
of 250mg/kg tribromoethanol, intubated and ventilated with 0.5-2% Isoflurane in 
combination with tribromoethanol. Mice were then provided with subcutaneous 
analgesia (buprenorphine SR at 0.5mg/kg) before undergoing a left thoracotomy 
performed by a left lateral incision and transection of the third rib. The left 
coronary artery was ligated with an 8-0 polyethylene suture tied perpendicular to 
the long axis of the heart to produce the ischemia. Mice were split into; 1) control 
MI (N=7); and treatment groups of 2) MI plus HAM Membrane (N=8) and 3) MI 
plus HAM injection (N=10). Control MI mice received no treatment while 
treatment groups were split as follows: Amnion Membrane (PalinGen Membrane 
by AmnioTechnology) application to epicardial surface and Amnion injection 
(PalinGen Kardia-Flow by AmnioTechnology) into the myocardium.  
 
Implantation of Human Amnion Material: 
Amnion Membrane: One square centimeter of the membrane was placed onto the 
myocardium over the area of ischemia and secured with two single mattress 
sutures. 
Intramyocardial Injection: A 30-gauge sterile beveled needle was inserted near the 
base of the heart and advanced into the ischemic myocardium to the right of the 
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left main coronary artery. Fifty microliters of solution were injected into the 
myocardium and held in place until the solution dissipated and the needle was 
withdrawn.  
 
Echocardiography: 
 Echocardiography was recorded at baseline (before surgery), 10-day post-
surgery, and 28-day post-surgery using LogicE Ultrasound to document the 
changes in cardiac functional performance33. B-mode echocardiography was used 
to produce 2-D views of the long axis of the heart and measure ejection fraction 
(EF), fractional shortening (FS) and left mid-ventricular posterior wall thickness 
(LVPW). Two-dimensional M-mode echocardiographic images from parasternal 
short-axis views at basal, mid-ventricular and apical locations were used to 
calculate the left ventricular internal diameter (LVID) and left ventricular volume. 
Measurements were obtained in triplicate and averaged in both systolic and 
diastolic phases. 
 
Immunohistochemistry and Histological Staining: 
Tissue harvest and preservation: 
Two mice, one control and one HAM membrane treatment were 
euthanized at day 10 post-op to examine the progression of the membrane 
integration. Four weeks post-operation, the rest of the mice (N=23) were 
anesthetized and sacrificed through cervical dislocation and vital organ harvest. 
After removing the heart, it was sliced down the center on the long axis and 
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incubated in 10% formalin for fixation before being placed in methanol to 
dehydrate. Tissue was then cleared with xylene and embedded in a wax block for 
sectioning. All tissues were cut at 5 µm and placed on charged Superfrost slides 
for staining. Sections were imaged on a Zeiss microscope (M1 model) through 
Axion Vision Software (version 4.72) and photos were merged using Adobe 
Photoshop to visualize the entire heart. 
 
Hematoxylin and Eosin (H&E):   
H&E was used for visualization of overall tissue morphology and cellular 
infiltration. Tissues were rehydrated in an ethanol gradient before staining with 
Richard Allen Hematoxylin and Eosin incubation for 30 seconds. Heart sections 
were then imaged in 5x light microscopy. 
 
Picrosirius Red (PSR):  
PSR was used for visualization of collagen as a marker for scar development. 
Nuclei were stained with Weigert’s hematoxylin before tissues were placed in 
picrosirius red for 1 hour. Hearts were visualized and imaged in fluorescent light 
microscopy at 5x under Alexa 488 and Texas red and overlaid to show both live 
tissue and PSR stained collagenous tissue. Quantification was performed using 
ImageJ Software to determine the pixel area of the differing colors. The left 
ventricular area was used as a normalization method. The Color Threshold 
function was used to calculate the area of the left ventricle and the area of 
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collagen in the left ventricle to give a percentage of collagen which was then 
presented as an average across each group.  
 
Anti-Interleukin-6 (IL-6) Antibody:  
IL-6 is a cytokine released due to tissue injury or infection32. IL-6 staining was 
used to visualize the amount of IL-6 cytokine present in the tissue in relation to 
these processes in order to assess the amount of immune response that occurs in 
each treatment group.  Antigen retrieval was performed using sodium citrate 
buffer (Dako 1x Solution) for 40 minutes at 95 ̊C. For blocking, tissue is 
incubated in 0.3% hydrogen peroxide (H2O2) in PBS for to block endogenous 
peroxidase activity and then incubated with 10% goat serum and 2% BSA in PBS 
for 60 minutes to reduce nonspecific background staining. For the primary 
antibody, a 1:300 dilution of rabbit anti-IL-6 was used overnight at 
4 ̊C.  Secondary antibody was incubated for 1 hour at 1:500 dilution of goat anti-
rabbit IgG HRP. To allow for visualization, slides were incubated with DAB 
chromogen for 5 minutes.  The chromogen interacts with the HRP enzyme 
conjugated to the secondary antibody, converting it to a brown product to be 
visualized. Tissue was counterstained with hematoxylin for 45 seconds to allow 
for visualization of nuclei. Once mounted, slides were imaged under light 
microscopy.  
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Anti-CD68 Antibody: 
CD68 is an antigen expressed by macrophages, which play a vital role in the 
progression of tissue necrosis due to inflammatory responses. Macrophages also 
release factors that activate fibroblasts and lead to scar formation. To evaluate the 
relative amount of macrophages present in the myocardium after MI and 
treatments, tissues were stained with anti-CD68 primary antibody. Antigen 
retrieval was performed using sodium citrate buffer (Dako 1x Solution) for 40 
minutes at 95 ̊C. Blocking was carried out using 0.3% H2O2 in PBS to block 
endogenous peroxidase activity and then incubated with 10% goat serum, 2% 
BSA in PBS for 60 minutes to reduce nonspecific background staining. The rat 
anti-CD68 primary antibody was diluted at 1:100 and incubated overnight at 
4 ̊C.  A 1:500 dilution of goat anti-rat IgG HRP was used for the secondary 
antibody and incubated for 1 hour. Six minutes of DAB chromogen was then used 
before counterstaining nuclei with hematoxylin. Slides were imaged under light 
microscopy at 10x-40x.  
 
Statistical Analysis: 
 All data was analyzed through a 2-Way ANOVA with multiple 
comparisons or mixed model analysis for significance. Significance was 
determined by a P-value < 0.05. Graphical error bars represent the standard error 
of the mean (±SEM). 
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Results  
 
Immunohistochemistry and Histological Staining: 
 H&E PSR IL-6 
Control:  
(Animal 
number 
519569-4) 
 
 
N=6 
 
 
 
HAM 
Membrane 
(Animal 
number 
519570-3) 
 
 
N=7 
   
HAM 
Injection 
(Animal 
number 
519572-1) 
 
 
N=8 
 
 
  
Figure 5: Histological comparisons between groups with H&E, PSR and IL-6 
staining. 
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Figure 6: H&E staining showed cellular accumulation at the epicardial surface at 
day 10 with the application of the HAM membrane to an infarcted heart (A) in 
comparison to the control MI (B).  
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Histological staining presented interesting results in both the membrane 
and injected HAM treated groups. With the HAM membrane group, we noticed 
that in multiple mice there was an appearance of tissue adhered to the ventricular 
wall. This tissue displayed an abundance of nuclei but did not display the typical 
morphology of collagen or cardiac muscle. In some mice, as displayed in Figure 
5 above, the injection of HAM led to a retention in myocardial tissue in hearts that 
clearly suffered a large ischemia due to the presence of the collagen and 
remodeling from near the top of the left ventricle to the apex of the heart. 
However, between the two areas of collagen development remained a visible 
patch of live myocardium as displayed by the PSR staining. IL-6 staining did not 
show any notable differences in amount of cytokine across the groups, or in 
comparison to the control MI mice.  
Figure 6 shows that the application of the membrane led to a significant 
accumulation of cells at the surface of the heart during a 10-day period. Since the 
dehydrated version of the HAM membrane was used which does not possess live 
cells, we know that this accumulation is due to cellular recruitment and/or growth.  
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Figure 7: Picrosirius red staining quantification shows the percent collagen in the 
left ventricle across treatment groups. Data is represented as mean values with 
error bars ±SEM. 
 
 Although the quantification of collagen did not show significant 
differences across groups, it should be noted that HAM treatment introduces a 
large quantity of collagen to the tissue which could counteract the reduction in 
scar formation and lead to the similar collagen quantities of the left ventricles in 
each group. Even with that in mind, the data shows a trend for the HAM 
membrane to lead to an increase in collagen in the left ventricle, while the 
injection of the material led to a decrease in the mean percent collagen (Figure 7). 
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 Echocardiography: 
Figure 8: A graphical representation of the changes in ejection fraction over time 
(A). B shows the scatter of data points for ejection fraction to emphasize the 
outliers and general trends. Error bars are representative of ±SEM. 
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Ejection fraction is commonly used as a measure for ventricular function. 
Ejection fraction is measured as the amount of blood that is contracted out of the 
ventricle in relation to the amount of blood that the ventricle contains at the end of 
relaxation. Ejection fraction is determined by measuring the volume of blood at 
end-systole and end-diastole, it is then expressed as a percentage of the blood at 
end-diastole that leaves the ventricle during contraction.  
A mixed-effects analysis with Tukey’s multiple comparisons showed 
significant improvement in ejection fraction between the HAM injection group 
and control at day 10 (p = 0.0298). Large variation in the control group prevented 
significant comparison to the HAM injection at day 28. Interestingly, the injection 
of HAM led to an increase in ejection fraction for several mice at the 10-day 
period and a single mouse at the 28-day measurement.  
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Figure 9: Fractional shortening was measured at the posterior mid-ventricular 
level using echocardiography. Data is represented as mean values normalized to 
baseline values with error bars ±SEM. 
 
 Fractional shortening (FS) represents a second method for determining 
systolic function of the ventricle. Fractional shortening recorded through two-
dimensional B-mode echocardiography is represented in Figure 9 through 
normalization of each data set to the baseline measurements. Statistical analysis 
was performed through a 2-way ANOVA with Tukey’s multiple comparisons test. 
This showed significant differences between the control and HAM injection (P = 
0.0179) as well as HAM membrane and HAM injection groups (P = 0.0034) at 
day 10. Although there is not a statistical significance between these groups at day 
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28, there is a visible trend of an increase in FS in the group treated with HAM 
injection.  
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Figure 10: Wall thickness was measured at the posterior mid-ventricular level 
during systole using echocardiographic imaging. Data is represented as mean 
values normalized to baseline values with error bars ±SEM. 
 
 Mid-ventricular wall thickness is a measure of determining the functional 
capabilities of the left ventricle, the retention of myocardial tissue, and dilation of 
the ventricular wall. When a permanently ligated MI is given to mice the ventricle 
dilates to severe degrees and the muscle loss leads to ventricular wall thinning. 
The reduction in wall thickness is shown in Figure 10 where values are 
normalized as a fraction of the baseline data. This wall thinning was observed 
across all groups, though the mean wall thickness is slightly higher in HAM 
treatment groups.  
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With this introduction of an ischemia, it is expected to lead to severe 
ventricular dilation as seen in the histological representations in Figure 5. This 
dilation was also measured as the internal diameter of the left ventricle through 
short-axis M-mode echocardiography. Internal diameter during systole represents 
a method of analyzing the contractile function in combination with the degree of 
dilation. Collected data is graphically represented in Figure 11 below as mean 
values across the groups. A Tukey’s multiple comparisons 2-Way ANOVA 
showed significant reduction in ventricular diameter during systole between the 
HAM injection group and the control (P = 0.0341) in addition to the HAM 
injection group and the HAM membrane group (P = 0.0264) after four weeks. 
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Figure 11: The internal diameter of the left ventricle of each treatment group 
measured during systole. Data is shown as mean values with ±SEM error bars. 
 
The reduction in dilation and conservation of contractile function is further 
supported by the ventricular volumes. The volume of the left ventricle is a second 
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method of measuring contractile function of the entire ventricle as well as its 
pathological dilation. Data is shown in Figure 12 below as mean values across 
treatment groups. A Tukey’s multiple comparisons 2-Way ANOVA showed 
significantly less ventricular volume between the HAM injection group and the 
control (P = 0.0196) in addition to the HAM injection group and the HAM 
membrane group (P = 0.0094) at day 28.  
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Figure 12: Volume of the left ventricle during systole. Data is shown as mean 
values with ±SEM error bars. 
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Discussion: 
This study showed that HAM injection into ischemic myocardium may 
lead to improvement in cardiac function in comparison to non-treated tissue. We 
noted a decrease in dilation of the left ventricle and retention of contractile 
function as shown by the reduced ventricular internal diameter and volume during 
systole. These results warrant further study to see if data trends will become 
significant changes across groups if given a larger N. Histological staining also 
showed a change in morphology of the tissue when treated with HAM as well as 
an accumulation of cells in the HAM treated areas. This led us to believe that the 
HAM membrane was engrafting into the tissue and that HAM was promoting 
cellular recruitment and growth. We believe that integration of the HAM 
membrane occurred which led to a development of nuclei-rich section of the left 
ventricle which could possibly lead to myocardial growth over a longer time 
period.    
CD68 staining did not show any significant changes in the presence of 
macrophages; the number of macrophages in the mice hearts was relatively low 
across all groups, but the activation of these monocytes is unknown. Picrosirius 
red fluorescently stains collagen and presents a solution for determining the extent 
of scar formation due to ischemia, however, when HAM is introduced to the 
tissue, whether it be through integration at the epicardial surface or injection, it 
introduces a large amount of collagen to the tissue. A large percentage of HAM is 
collagen, so by introducing it to the tissue it is likely that it then brings up the 
percent collagen in the ventricular wall, even though that collagen is not related to 
the scar formation. Therefore, it is reasonable to see that the percent of collagen 
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would not differ between groups, even if the scar formation is lessened in HAM 
treated tissues.   
Injection into beating myocardial tissue only a couple millimeters in width 
is a difficult and not always successful task. Although measures were taken to 
promote the injection staying in the tissue, there is not a way of knowing the 
amount of injected material that remained in the tissue, dispersed, or leaked out of 
the injection site. These limitations provide room for improvement in the 
experimental design and reason for expansion to a larger N and larger species. 
  
- 37 - 
 
Chapter 3: In vivo Swine Model 
 
Introduction: 
 In this chapter I will review the experimental application of HAM in an in 
vivo ischemic swine model. First, it is important to note the additional treatments 
that were applied in this study. In addition to HAM, Platelet-Rich Plasma (PRP) 
and Trans-myocardial laser Revascularization (TMR) were used as supplemental 
treatments to HAM injection. PRP is derived from the centrifugation of whole 
blood and contains a large number of platelets in a small amount of plasma, as 
indicated by its name. Platelets provide a source of growth factors, so PRP is a 
dense accumulation of growth factors such as platelet derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF), and platelet derived 
angiogenic factor (PDAF)34. These growth factors have a vital role in healing 
processes, most notably proliferation and angiogenesis35. Platelets also contribute 
fibronectin, vitronectin and other substances that are key initiators of wound 
healing34. It has also been reported that PRP may provide a potential fibrin and 
platelet regenerative matrix to advance healing pathways36. The benefits of PRP 
remain controversial as studies have not provided strong evidence of its efficacy 
and introducing growth factors can promote tumor growth. However, we 
hypothesized that using PRP as a suspension solution for HAM injection would 
provide additional growth factors and substances beneficial to wound healing, and 
any risks would be counteracted by anti-tumorigenic properties of HAM37.  
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 We also hypothesized that TMR would add to the benefits of HAM 
injection when combined as a treatment. TMR has been used since the early 90’s  
to initiate revascularization and improve perfusion38. The general concept of TMR 
is to create an artificial pathway for blood to reach areas of ischemia39. 
Myocardial perfusion has been reported to increase by 20 percent in patients 
treated with TMR. The idea of combining TMR treatment with HAM injection 
was that increased perfusion could enhance myocardial preservation and provide 
vessel formation for increased HAM integration into the tissues. A porcine animal 
model offers advantages such as similarities to humans in terms of organ sizes, 
coronary anatomy and immunologic responses40. A large surface area and ease of 
multiple, separated injections was necessary for this experiment, making the 
swine the most translatable and readily available animal model that could be used.  
 
Materials and Methods   
Experimental Design: 
Experiments were approved by IACUC at the University of Arizona 
(protocol number: 17-217) and adhered to guidelines for care and use of 
laboratory animals. The main purpose of this study was to be a pilot study to serve 
only as a proof-of-concept and establishment of protocols for further 
investigation. Therefore, the study included a small sample size with a large 
number of treatments per animal. Tissues were separated into treatment sites, 
meaning the non-treatment areas served as control tissue.  
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Surgical Procedure:  
Six-month-old domestic farm pigs (n=3) ranging from 54.7 – 58.75 Kg, 
received bupivicain at 2mg/Kg and lidocaine at 4-6 mg/Kg for local and regional 
analgesia. The animals then underwent 45-minute percutaneous ischemia 
reperfusion via balloon occlusion distal to the second diagonal of the Left 
Anterior Descending artery (LAD) under fluoroscopic guidance.  
Seven days post-ischemia, animals were sedated with ketamine 10-
18mg/Kg and diazepam 1-2 mg/Kg, induced with 5% isoflurane in O2 via mask 
and anesthetized with 1-2.5% isoflurane in O2 via endotracheal tube before being 
placed in dorsal recumbency for median sternotomy to expose the heart. 
Lidocaine 2 mg/Kg IV bolus every 30 minutes along with fentanyl 0.003 mg/Kg 
IV bolus loading dose with constant rate infusion of 0.001-0.003 mg/Kg/hour was 
administered for pain management. In addition, buprenorphine HCl 0.01-0.05 
mg/Kg intramuscular for analgesia at vet discretion.  
Animals were scheduled for euthanasia after being sedated and 
anesthetized via KCl IV at 1-2 mmol/Kg in conjunction with isoflurane at post-
operative day 1, 2 and 7 following second survival surgery.  
 
Treatment Groups: 
 Treatments included an injection of two variations of HAM, which were 
referred to as particulate and viable. The particulate is a micronized and 
suspended form of the dehydrated amnion/chorion material. The viable is a 
suspension of the live amnion layer. One aim of this study was to test if 
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treatments could be further augmented through the addition of other methods 
known to induce healing and promote regenerative processes. Therefore, PRP and 
TMR were added to treatment sites to examine a local combined effect leading to 
further enhancement of tissue preservation and regeneration. PRP was used as an 
alternative solution for saline in suspension of HAM. TMR was added close to the 
injection site to investigate the combination of treatments. Treatments were 
grouped as follows: Control, PRP, TMR, PRP and TMR, Particulate in saline, 
Viable in saline, Particulate in PRP, Viable in PRP, Particulate in saline with 
TMR, Viable in saline with TMR, Particulate in PRP with TMR, and Viable in 
PRP with TMR. Each animal received all of the above treatments in the infarcted 
zone at different sites to create an N of 3 for each treatment. Each injection was 
500 microliters of equal concentration of HAM. For Particulate suspension, 
dehydrated Amnion/Chorion matrix was micronized and thoroughly mixed with 
the suspension solution.  
 
Tissue collection and preservation: 
 Following euthanasia, the sternum was re-opened, the heart was excised 
and washed with heparinized saline, and treatment sites were cored out of the 
heart and embedded in OCT, then frozen in liquid nitrogen and stored at -80 ̊C. 
All tissues were sectioned at 5 micrometers in -20 ̊C, placed onto charged slides, 
and stored overnight at -80 ̊C before proceeding with fixation and staining.  
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Immunohistochemistry and Histological Staining: 
Hematoxylin and Eosin (H&E):   
H&E was used to visualize the morphology of the tissues as well as 
neutrophil and cell accumulation in the tissue. Tissues were fixed in 100% 
methanol at -20 ̊C for 15 minutes before rehydration and Richard Allen 
Hematoxylin for 5 minutes for nuclei staining. Tissues were incubated in Eosin 
for 25 seconds to stain the cytoplasmic elements. Treatment sections were then 
imaged in 5x light microscopy and stitched using Photoshop.  
 
Picrosirius Red (PSR):  
PSR was used for collagen quantification as an indication for scar 
formation. Tissue sections were fixed in 95% methanol 5% acetic acid at -20 ̊C 
for 15 minutes. Nuclei were stained with Weigert’s hematoxylin before tissues 
were stained with picrosirius red for 30 minutes. Tissues were then imaged in 
fluorescent light microscopy at 5x under Alexa 488 and Texas red and overlaid. 
Quantification of pixel area for collagen and live tissue was performed using 
ImageJ Software after Photoshop stitching. Quantification was performed by 
finding the pixel area for both green and red fluorescence using the Color 
Threshold function on ImageJ software. The sum of the live tissue (green) and 
collagen (red) was used as the total tissue area and the amount of collagen was 
then divided by total tissue area to give a percentage of collagen within the tissue 
section. This was presented as an average percentage for each group.  
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Results  
Immunohistochemistry and Histological Staining: 
 Histological staining did not show any noticeable trends across treatment 
groups. We did not notice any large areas of increased cellular accumulation as 
was expected in the HAM treated tissues. However, some tissues showed small 
pockets that did not have muscle tissue but were dense with nuclei, shown by 
H&E staining. This could indicate pockets of the injection that had yet to 
disperse. Further investigation is required to see if these were observed in control 
tissue. PSR staining did show collagen formation at TMR sites especially, 
however these sites can be difficult to distinguish from larger vessels. Histological 
comparisons across representative treatment groups are shown below in Figure 
13.  
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Figure 13: Histological comparisons between representative treatment groups 
with H&E and PSR.  
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Figure 14: Percent collagen as determined my picrosirius red staining 
quantification in the tissue cores across treatment groups. Data is represented as 
mean values with error bars ±SEM. 
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PSR staining quantification showed no significant differences across 
treatment groups, however TMR groups tended to have a larger mean percentage 
of collagen as predicted by histological observations. Figure 14, A and B both 
represent percent collagen in the tissue, A shows the different HAM treatments 
across combinations of the additional treatments to emphasize the differences 
between control and HAM treatments. 
 
Discussion: 
 This pilot study did not suggest any strong trends of data or observations. 
This study served the purpose of working out the experimental design and 
protocols for the combination of treatments in an ischemia reperfusion swine 
model to expand the study for our nest steps in swine models with HAM treated 
infarcted hearts. Limitations of this study included the small sample size as well 
as the timeline of the treatments. Inflammation and POAF reach their peak levels 
at post-operative days two and three, so a timeline stretched out around those days 
was chosen for comparison. Each animal was scheduled for a different timeline of 
euthanasia to assess the relatively acute effects of the treatments of up to one 
week. However, due to the strain on the animals, two of the pigs that were 
scheduled for euthanasia at days 2 and 7 died shortly after the second survival 
procedure. The first pig was euthanized at 24 hours post-op, the second and third 
pigs died approximately 3 hours after the median sternotomy and treatment 
application procedure. This led to an even shorter timeline than originally 
planned, and possibly not enough time for each treatment to take effect. Another 
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challenge that we faced was the preservation and fixation of the material. The first 
set of tissue that was collected suffered areas of freeze damage that was later 
corrected in the next tissue collection and preservation protocols for the last two 
animals.  
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Chapter 4: General Discussion  
 
Previous chapters reviewed literature pertaining to the current uses of 
Human Amniotic Membrane as well as its noted potential in cardiac application 
through animal models. Limited literature is available on the cardiac applications 
of HAM and the mechanism for its contribution to remodeling pathways are still 
unknown. I then discussed our application in human cardiac patients to prevent 
POAF and went over our use of HAM in MI animal models to demonstrate its 
abilities to preserve myocardial tissue and function. These experiments served as 
proof-of-concept pilot studies in which amniotic material was applied to ischemic 
hearts to examine response mechanisms triggered or suppressed by the presence 
of the material. This was done in order to gain a more thorough understanding of 
the observation that its use in cardiac surgery patients dramatically reduced the 
occurrence of POAF. This chapter will discuss the observed results of the studies 
performed, speculation into the mechanisms behind these observations and 
possible methods for enhancing outcomes.  
Through the use of a four-week permanent ligation mouse model we came 
to the conclusion that HAM injection may offer a solution to improving the 
retention of myocardial function after ischemia. Our data suggests HAM injection 
leads to a preservation of the contractile function and a decrease in pathological 
remodeling as shown by a larger retention in fractional shortening and reduced 
dilation of the left ventricle. This was measured through the left ventricular 
internal diameter and volume during systole. These results are further supported 
by the trends of the ejection fraction, fractional shortening and wall thickness. 
- 48 - 
 
One unexpected observation was the increase in ejection fraction over the 10-day 
and 28-day period in some mice. We believe that this was due to the injection of 
HAM helping to preserve the myocardial function. However, it is important to 
point out that the functionality of the muscle was retained in these animals, and 
the group of mice that received the HAM injection showed a visible reduction in 
the mean percent decrease in ejection fraction. The control group was much more 
variable, we saw outliers in the control group that lost much more of their 
contractile function than was seen in any of the HAM injection animals.  
A second notable observation was seen in the histology of the mice hearts. 
We saw a strong accumulation of cells at the epicardial surface when treated with 
HAM membrane. This was seen at 10-day post-operation, and even more so at the 
28-day marker. At day-28 we noticed that in multiple mice there was an 
appearance of tissue at the location treated with HAM membrane on the 
ventricular wall. This tissue contained a dense accumulation of nuclei but not 
typical muscle or collagen morphology, so we believe it to be a result of HAM 
infiltration of the myocardium. This supported the idea that HAM would integrate 
into the myocardium and lead to regeneration, instead of simply being degraded 
by the body. This suggests that cellular recruitment and growth was an effect of 
HAM membrane integration into the myocardial tissue. The injection of HAM 
resulted in retention of cardiac muscle tissue in hearts that showed a large visible 
ischemic area through the scar formation that developed around the injection site. 
IL-6 staining did not show any notable differences in amount of cytokine across 
the groups, meaning that HAM did not elicit a larger immune response in HAM 
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treated tissues. This supports the claims of HAM’s low immunogenic properties 
but did not illustrate further suppression of the immune response as expected.  
 
Speculations: 
 Further speculation of the mechanism behind our data is that the primary 
contribution of HAM when applied to ischemic myocardium is its anti-fibrotic 
effects. The injection of HAM supported this claim through histological 
comparison to control MI hearts. Control MI mice showed ventricular wall 
remodeling into a thin section of collagen lacking contractile function. In the 
HAM injected MI model, we saw collagen surrounding the area of injection 
indicating the suppression of scar formation in the injected area. In addition, the 
anti-inflammatory properties may contribute to limiting the death of the 
cardiomyocytes in these injection sites. We also believe that if the model were 
extended to a longer timeline that the HAM membrane group may experience 
rebuilding of the myocardial wall due to the integration of the membrane and 
growth of cells that was observed. This growth is likely due to the abundance of 
growth factors available to the tissue through the application of HAM. Therefore, 
it is believed that the growth will lead to improvements in cardiac function long-
term if the model was given a longer timeline.  
 A recent publication has shown that pericardial closure during surgery 
using an extracellular allograft scaffold has led to a reduction in POAF41. The 
proposed mechanism behind this research is that the closure of the pericardium 
provides a barrier that prevents infiltration of cellular debris and therefore 
- 50 - 
 
inflammation of the pericardium. However, pericardial closure has been strongly 
correlated to the occurrence of cardiac tamponade, so this method can be risky 
and the widely preferred method is to refrain from stitching the pericardium42. 
Our goal was to prove that the application of HAM served as more than a 
pericardial barrier, which supported by the injection of the material leading to 
significant retention of systolic contractile properties. The use of HAM is superior 
to that of the extracellular matrix barrier used in the study for several reasons. 
Primarily, in addition to a barrier, it provides anti-fibrotic and inflammatory 
suppressing factors which further the contributions to reducing scar formation and 
development of POAF. We saw this reduction in POAF occurrence without 
stitching it to the pericardium, meaning the risk of cardiac tamponade due to 
pericardial closure is eliminated with the use of HAM. In addition to this, HAM 
provides a variety of growth factors to support healing and angiogenesis which is 
predicted to improve cardiac function long-term. HAM has also been proven to be 
equally compatible as autologous skin grafts, superior to other allografts, so HAM 
is likely to elicit less of an immune response than the extracellular allograft29. 
These speculations can be proven by future study into HAM application in cardiac 
disease.  
  
Future Directions: 
The two animal studies that were performed were pilot studies that left 
substantial room for expansion and improvement. Although the data visually 
supports our hypotheses, but some do not show statistical significance, the 
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reduction in error through a larger sample size could possibly lead to a 
confirmation through statistical analysis. It is reasonable to believe that this larger 
sample size would lead to more reliable results in order to differentiate more 
clearly between groups.  In addition to increasing the sample size, the inclusion of 
a second species of rodent would be beneficial to further supporting the trends of 
the initial data. Rats present a larger rodent model allowing for a larger surface 
area to work with and thicker ventricular wall for injection. It is also planned to 
further the swine study in both acute and chronic remodeling. Our next steps with 
the swine models will be to identify acute functional differences and 
inflammatory modulation seen in HAM treated ischemic tissues. Finally, we will 
study HAM implications in long term remodeling and functional outcomes in an 
infarcted swine model. In order to prove the material’s superiority over an 
extracellular matrix use in pericardial closure, it will also be necessary to add in 
control groups provided with these barriers.  
Eventually, it would be interesting to test the ability of HAM application 
in a wider range of cardiac procedures. For instance, Percutaneous Coronary 
Intervention (PCI) is an alternative method to CABG to increase blood flow to an 
ischemic area of the heart. PCI utilizes a catheter insertion of a stent into the 
blocked artery to expand the artery and restore blood flow43. Because this 
procedure is not an open-heart surgery, HAM application would be trickier. This 
is where it would be interesting to test the use of catheter injection of HAM 
during cardiac catheterization surgeries. Recent studies have opened up the 
possibility of doing this through the use of the PHOENIX ™ system44. Although 
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PCI procedures do not require puncturing the pericardial sac and therefore would 
not require treatment for inflammation or POAF caused by this, the results 
reported in this thesis indicate that HAM may contribute more to cardio-
protection, retention of cardiac function and myocardial regeneration than 
originally hypothesized. Treatment of ischemic cardiac tissue with HAM presents 
an exciting possibility for improving cardiac disease treatment methods. 
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